88results about "Angiogenesic factors" patented technology

Provided are an siRNA inhibiting the expression of an amyloid precursor protein (APP) gene in a human cell, a polypeptide-oligonucleotide drug, and a use. The siRNA has good APP expression inhibitory activity, and a suitable modification is made to the siRNA to improve the silencing capability against a target and reduce off-target activity. The siRNA and a conjugate thereof are expected to be applied for clinically preventing and treating an APP target-related disease such as cerebral amyloid angiopathy (CAA), early-onset familial Alzheimer's disease (EOFAD), or Alzheimer's disease (AD).

According to the present invention, the siRNA and the polypeptide oligonucleotide drug for inhibiting the expression of the amyloid precursor protein (APP) gene in the human body cell, and the application thereof are provided, the siRNA has good APP expression inhibition activity, and can improve the target silencing ability and reduce the non-target activity through the appropriate modification; the siRNA and the conjugate thereof are expected to be applied to prevention and treatment of diseases such as cerebral amyloid vascular disease (CAA), early onset familial Alzheimer's disease (EOFAD) or Alzheimer's disease (AD) which are related to APP targets clinically.

To provide compositions for gene modification or editing and methods of using the same to treat or prevent certain conditions.SOLUTION: Specific compositions and methods are disclosed, capable of safely and effectively editing gene targets expressed in a liver, to durably lower LDL-C, thereby treating a leading cause of a cardiovascular disease.SELECTED DRAWING: Figure 34-1

The present invention relates to the treatment of infectious diseases. In this study, we identify potential defense mechanisms involved in maintaining brain vascular integrity during bacterial infection and perform RNA analysis of primary endothelial cells isolated from human skin (HDMEC) or brain (HBMEC) microvessels. The cells were either uninfected or infected with Neisseria meningitidis in vitro. We found 40 genes, especially ANGPTL4, that are specifically regulated in brain endothelial cells during infection. In the context of sepsis, ANGPTL4 was found to be the main barrier stabilizing protein with a defensive effect against bacterial infection. ANGPTL4 (or derived peptides) also showed potential as an adjunctive therapy to reduce bacteria-induced vascular dysfunction and mortality. Thus, the present invention relates to peptides derived from the protein ANGPTL4 and their use in the treatment of infectious diseases.

The present application provides ex vivo or in vivo materials and methods for treating a patient suffering from one or more conditions associated with ANGPTL3. In addition, the present application provides materials and methods for editing and / or modulating the expression of the ANGPTL3 gene in a cell by genome editing.

A composition for editing the PCSK9 gene comprises: (i) an mRNA encoding a protein comprising a programmable DNA binding domain; and (ii) a guide polynucleotide, wherein the guide polynucleotide compr

Anti-angiopoietin-like protein (ANGPTL) 3 / 8 complex antibodies are provided that can be used to treat diseases and disorders related to lipid metabolism and glucose metabolism. [Solution] Antibodies that bind to the human ANGPTL3 / 8 complex are provided, which include light chain determining regions LCDR1, LCDR2, and LCDR3, and heavy chain determining regions HCDR1, HCDR2, and HCDR3, each having a specific amino acid sequence. Pharmaceutical compositions containing one or more anti-ANGPTL3 / 8 complex antibodies of the invention in a pharmaceutically acceptable carrier are also disclosed. Methods of making and using the above, particularly for increasing lipoprotein lipase activity and lowering triglycerides, are also disclosed.

The invention discloses an application of a substance taking Angpt18 as a target in preparation of a medicine for treating and delaying senescence, and the key regulation effect of an Angpt18 gene in the occurrence and progression process of normal senescence and senescence-related diseases is found for the first time through systematic and in-depth research; further experiments prove that by inhibiting or down-regulating the expression of the Angpt18 gene, the senescence process can be obviously delayed, and the expressions such as hypomnesia and behavioral ability decline in the senescence process can be effectively improved. Therefore, the Angpt18 gene can be used as an important intervention target for senescence and related diseases thereof, can be used for developing drugs with senescence delaying or treatment effects, can also be used as a biomarker for evaluating the senescence degree and diagnosing and prognosing the related diseases of senescence, and has wide application prospects and clinical transformation values.

The present invention provides siRNA, peptide oligonucleotide drugs, and their applications for suppressing the expression of the amyloid precursor protein (APP) gene in human cells. The siRNA exhibits potent activity in inhibiting APP expression. Through appropriate modifications, its ability to silence the target is enhanced while reducing off-target activity. The described siRNA and its conjugates hold promise for clinical application in the prevention and treatment of diseases associated with the APP target, including cerebral amyloid angiopathy (CAA), early-onset familial Alzheimer's disease (EOFAD), or Alzheimer's disease (AD).

Provided herein are compositions comprising an oligonucleotide that targets ANGPTL7. In some embodiments, the oligonucleotide includes modified nucleotides. In some embodiments, the oligonucleotide may be used to reduce intraocular pressure in a subject's eye.

Angiopoietin-like protein (ANGPTL)3 / 8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3 / 8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3 / 8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.

The invention relates to the technical field of feeding of acipenser sibiricum, in particular to an acipenser sibiricum appetite promoting factor angiopoietin-like protein and application thereof, in-vitro prokaryotic recombinant expression of ANGPTL4 mature peptide is achieved for the first time, and acipenser sibiricum ANGPTL4 / pET-32a protein with biological activity is obtained through purification. The provided Acipenser sibiricum ANGPTL4 / pET-32a recombinant protein can lay a foundation for subsequent research on biological functions of ingestion regulation and control.

The present invention discloses a biomarker for predicting the efficacy of tumor immunotherapy and its application, which relates to the field of biomedicine technology. The biomarker is secretory frizzled-related protein 2 of tumor-associated fibroblasts. The present invention systematically reveals the function of secretory frizzled-related protein 2 of tumor-associated fibroblasts in the tumor microenvironment from multiple dimensions such as cell subpopulations themselves, interactions with the microenvironment, and spatial distribution characteristics, and confirms that secretory frizzled-related protein 2 of tumor-associated fibroblasts can be used as a biological marker to effectively predict the efficacy of tumor immunotherapy. This has important clinical value and significance for the early evaluation of the efficacy of immunotherapy in clinical tumor patients and the formulation of individualized treatment plans, and ultimately improving the survival rate of tumor patients.

The present disclosure relates to an siRNA for inhibiting the expression of an angiopoietin-like protein 3 (ANGPTL3) gene, an siRNA conjugate, and a pharmaceutical composition thereof, and a method for reducing the expression of the ANGPTL3 gene by using the siRNA, the siRNA conjugate, and the pharmaceutical composition thereof. The siRNA, the siRNA conjugate, and the pharmaceutical composition thereof of the present disclosure can be used for treating and / or preventing an ANGPTL3 gene-mediated disease or disorder.

A method of inducing lymphangiogenesis in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of inducing lymphangiogenesis in a tumor in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of treating a cancer of the brain or central nervous system is also provided in which an effective amount of a lymphangiogenesis inducer is administered. An example of a lymphangiogenesis inducer is VEGFC. The lymphangiogenesis inducer can be in the form of a protein or a polynucleotide encoding the protein, such as an mRNA or AAV. The lymphangiogenesis inducer can be administered to the cistema magna or directly into the lymphatic system. An immunotherapeutic agent, such as a checkpoint inhibitor, may also be administered.

The present invention provides a novel blood-derived growth-factor-containing composition. The present invention for solving the above problem is a method for preparing a growth-factor-containing composition from blood, the method comprising a step for separating platelet-rich plasma that does not contain a buffy coat component from the blood, and a step for adding citric acid and / or a salt thereof to the blood or a processed product thereof.

The present invention relates to productive tissue repair and regeneration, and in particular poylpeptides, compositions including said polypeptides, and methods of using said polypeptides or compositions for productive tissue repair and regeneration. In one aspect, the invention provides a polypeptide comprising, consisting essentially of or consisting of a C-terminal portion of NAMPT comprising a truncated cytokine finger motif (cif) motif. In another aspect, the present invention provides a fusion protein comprising, consisting essentially of or consisting of a polypeptide of a full length NAMPTcif or truncated variants and a tissue delivery or retention enhancing moiety.

The invention relates to the field of wound tissue repair, and discloses an ANGPTL-7 recombinant protein, a gene, a recombinant vector, a recombinant strain, a composition and applications thereof. The recombinant protein has an amino acid sequence selected from any one of the following (a)-(c): (a) an amino acid sequence as shown in SEQ ID NO: 1; (b) a derivative protein obtained by substitution, deletion or addition of at least one amino acid to the amino acid sequence represented by SEQ ID NO: 1, wherein the protein activity of the derivative protein is not lower than 95% of the protein activity of (a); (c) an amino acid sequence of which the amino terminal and / or carboxyl terminal of the amino acid sequence (a) or (b) are / is connected with a label; and (d) an amino acid sequence formed by connecting a signal sequence to the amino terminal of the amino acid sequence (a) or (b). The recombinant protein can promote tissue repair and accelerate wound healing, and is expected to be widely applied to clinical treatment.

The invention provides a growth factor-dextran conjugate as well as a preparation method and application thereof, the growth factor-dextran conjugate consists of a growth factor and dextran, and is obtained by coupling an amino group of the growth factor and a hydroxyl group of the dextran through a chemical reaction; the growth factor-dextran conjugate can protect the growth factor to enhance the stability of the growth factor, reduce the degradation of the growth factor in vivo and prolong the in vivo half-life period of the growth factor; coupled dextran can be combined with a cell surface receptor to promote cellular uptake of growth factors and enhance the effective action concentration of the growth factors in cells, has good biocompatibility and biological safety, and has wide application in research and development of drugs for wound repair and / or treatment of neurodegenerative diseases.

Compositions and methods are disclosed which comprise a guide polynucleotide corresponding to a protospacer sequence on the Angiopoietin-like protein 3 gene with a view to base editing the Angiopoieti

A composition for editing the PCSK9 gene comprises: (i) an mRNA encoding a protein comprising a programmable DNA binding domain; and (ii) a guide polynucleotide, wherein the guide polynucleotide compr

Provided herein are methods for assaying the chondrogenesis-inducing activity of a therapeutic by measuring the expression and / or secretion levels of chondrogenesis biomarkers.

To provide methods of treating patients having an ophthalmic disease, methods of identifying a subject having an increased risk of developing an ophthalmic disease, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.SOLUTION: A method of treating a patient having increased IOP comprises administering an angiopoietin like 7 (ANGPTL7) inhibitor to the patient.SELECTED DRAWING: Figure 6A

The present invention relates to the field of nucleic acid editing, in particular the field of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. In particular, the present invention relates to Cas effector proteins, fusion proteins comprising such proteins, and nucleic acid molecules encoding them. The present invention also relates to complexes and compositions for nucleic acid editing (e.g., gene or genome editing) comprising the proteins or fusion proteins of the present invention, or nucleic acid molecules encoding them. The present invention also relates to methods for nucleic acid editing (e.g., gene or genome editing) using complexes comprising the proteins or fusion proteins of the present invention.

The present invention pertains to the use of gene editing and miRNA technologies for improving recombinant production of ANGPTL3 mimetics in CHO cells. The gene expression modifications are used for knock-out / knock-down of the endogenous protein CCL2 of the CHO cells which is difficult to separate from ANGPTL3 mimetics during purification.

Compositions and methods are disclosed which comprise a guide polynucleotide corresponding to a protospacer sequence on the Angiopoietin-like protein 3 gene with a view to base editing the proprotein

Provided herein are compositions comprising an oligonucleotide that targets ANGPTL7. In some embodiments, the oligonucleotide includes modified nucleotides. In some embodiments, the oligonucleotide may be used to reduce intraocular pressure in a subject's eye.